ALK rival in clinical setback
ALK’s French rival Stallergenes has seen disappointing results from a trial with its oral vaccine against house dust mite allergy. It could spell either good or bad news for the Danish company.
BY STEFAN SINGH KAILAY
When your biggest rival fails in its clinical development of a product aimed at a massive market, you might think that it would be cause for celebration. But that is not necessarily the case for Denmark’s ALK after its French rival Stallergenes announced a spot of bad news to the market Monday.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
”It’s celebration day out here”
For abonnenter
ALK heading to FDA with dust mite vaccine
For abonnenter
